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Abstract 
The study aimed to determine the clinical and neuropsychological predictors 
of responsiveness to cognitive behavioural therapy for psychosis (CBTp). Sixty 
patients with schizophrenia or schizoaffective disorder and 25 healthy individuals took 
part in the study. Thirty patients (25 protocol completers) received CBTp in addition 
to standard care (SC); 30 patients (18 protocol completers) received SC only. All 
patients were assessed on symptoms using the Positive and Negative Syndrome 
Scale (PANSS) and clinical and neuropsychological function before and after CBTp. 
Symptoms and self-esteem improved to a greater extent in the CBTp+SC than SC 
control group. Greater pre-therapy coping ability and the self-reflectiveness 
dimension of cognitive insight at baseline predicted improvement in symptoms in the 
CBTp+SC group, but not the SC control group, explaining up to 21% of the variance 
in symptom improvement. Pre-therapy neuropsychological function, duration of 
illness, clinical insight and gender did not predict CBTp responsiveness. Being able 
to have a range of coping strategies and reflect on one's experiences while refraining 
from overconfidence in one's interpretations before therapy is conducive to better 
CBTp responsiveness. 
Keywords: Coping skills, Cognitive Behavior Therapy, Psychosis 
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1. Introduction 
The extent to which neuropsychological and clinical factors determine 
responsiveness to cognitive behavioural therapy (CBT) for individuals with a 
psychotic disorder remains unclear. Seven randomised controlled trials (RCTs) have 
examined the clinical predictors of CBT for psychosis (CBTp) (Brabban et al., 2009; 
Emmerson et al., 2009; Garety et al., 1997; Naeem et al., 2008; Perivoliotis et al., 
2010; Tarrier et al., 1993; Tarrier et al., 1998) (see supplementary material for a 
summary of the studies), but have yielded somewhat contradictory findings. 
Tarrier et al. (1993) found that greater pre-therapy positive symptom severity 
predicted greater positive symptom improvement following CBTp. In contrast, Naeem 
et al. (2008) combined the results of two relatively large RCTs of CBTp versus 
treatment as usual in the Insight trial (N= 422) and versus befriending in the London 
Newcastle trial (N=90), and in the Insight trial, reported that lower pre-therapy general 
psychopathology predicted the greater likelihood of a good treatment outcome in the 
CBTp group, defined as a 25% improvement in general psychopathology. Tarrier and 
his colleagues (1998) found that the likelihood of a 50% improvement in positive 
symptoms was predicted by a shorter duration of illness in those receiving CBTp 
compared to routine care or supportive counselling, while Garety et al. (1997) found 
no relationships between length of illness or age of onset and outcome, but observed 
that a greater number of admissions in the previous five years was related to 
improvement in positive symptoms. Brabban et al. (2009) reported that being female 
was associated with a greater likelihood of improvement in general psychopathology, 
while again Garety et al. (1997) did not. 
There are, however, more consistent results showing that some aspects of 
insight may be related to good outcome in CBTp. Both Garety et al. (1997) and 
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Brabban et al. (2009) showed that cognitive flexibility about delusions, i.e. 
acknowledging that another view of the delusion may be possible, and having lesser 
conviction in one's delusional beliefs, were associated with a greater likelihood of 
improvement. Naeem et al. (2008) found that better pre-therapy insight into 'illness' 
predicted good outcome in the Insight study. Emmerson et al. (2009) found that 
greater clinical insight [awareness that the patient has a mental illness or specific 
symptoms, awareness of need for treatment, and attribution of symptoms to mental 
illness, as assessed by the Birchwood Insight Scale (BIS, Birchwood et al., 1994)] at 
baseline predicted greater improvement in independent living skills following CBTp, 
while Perivoliotis et al. (2010) reported that greater cognitive insight (the patient's 
ability to reflect on his/her experiences and recognise that conclusions may be 
incorrect), in particular self-reflectiveness (Beck Cognitive Insight scale, BCI, Beck et 
al., 2004), was associated with an improvement in severity of delusions and auditory 
hallucinations. While the Garety et al. study (1997) did not find that clinical or illness 
insight was predictive of good outcome, insight into the social consequences of one's 
illness predicted improvements in the CBTp group. 
Neuropsychological ability in the form of general intelligence or specific 
neuropsychological functions, such as memory, attention and executive function, may 
also play an important role in the therapeutic success of CBT. Neuropsychological 
impairment in individuals receiving therapy for alcohol dependence, for example, can 
impede acquisition of new coping behaviours (McCrady and Smith, 1986) or learning 
and retention of new material (Alterman and Hall, 1989). Three studies (Garety et al., 
1997; Granholm et al., 2008; Penades et al., 2010) (see Appendix for a summary of 
the studies) examined pre-therapy neuropsychological predictors of CBTp response 
in patients with a schizophrenia or schizoaffective disorder diagnosis, of which two 
studies (Garety et al., 1997; Penades et al., 2010) targeted symptom improvement, 
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while Granholm et al. (2008) targeted dysfunctional performance beliefs that 
interfered with social functioning. Penades et al. (2010) reported that schizophrenia 
patients who showed a reliable improvement in symptoms had greater pre-therapy 
verbal memory than non-improvers. Neither Garety et al. (1997) nor Granholm et al. 
(2008) found that IQ or neuropsychological performance were predictive of good 
outcome. However, Garety et al. (1997) did not use a comprehensive 
neuropsychological battery, while CBT in the Granholm et al. study (2008) did not 
target symptom reduction. 
One area which has not been investigated in CBTp outcome research is 
coping style. Coping enhancement has formed a part of some forms of CBTp 
(Andres et al., 2003; Tarrier et al., 1993; Tarrier et al., 1998) and been associated 
with better therapeutic outcome than standard care (SC) or supportive counselling. 
Patients' mastery of active, problem-focused coping strategies immediately after 
completion of therapy is reported to predict better psychopathological and social 
outcome 12-18 months after therapy (Andres et al., 2003). The successful acquisition 
of coping strategies during therapy may be dependent on an individual's pre-existing 
coping style, thereby influencing therapeutic outcome. No study, to our knowledge, 
has yet examined the role of coping styles in CBT responsiveness in psychosis. 
The present study aimed to determine the pre-therapy clinical and 
neuropsychological predictors of CBTp responsiveness in patients with schizophrenia 
or schizoaffective disorder. Based on earlier findings and the literature about the role 
of coping in CBTp, we tentatively hypothesized that a shorter duration of illness, 
better cognitive insight, more active coping, greater verbal memory and cognitive 
flexibility at baseline would be associated with better CBTp responsiveness, as 
measured by significant clinical improvement on the Positive and Negative Syndrome 
Scale (PANSS, Kay et al., 1987). The study also examined the change in clinical 
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status and neuropsychological function following CBTp. It was hypothesized that 
symptoms and cognitive insight would improve following CBTp, since improvement in 
symptoms was associated with greater cognitive insight in two previous studies 
(Granholm et al., 2002; Perivoliotis et al., 2010). 
2. Methods 
2.1. Participants and design 
Participants were 60 outpatients with a DSM-IV diagnosis of schizophrenia or 
schizoaffective disorder who were willing to receive CBTp in addition to their usual 
care. Twenty-five healthy participants were also included in order to characterize the 
patient group. The patient and healthy participant groups were matched on average 
for age and sex. Data on the improvement of symptoms in the CBTp+SC group 
compared to SC control group following CBTp have been reported in our recent 
reports on the functional MRI predictors (Kumari et al., 2010; Kumari et al., 2009) and 
structural MRI predictors of CBTp responsiveness (Premkumar et al., 2009). Thirty 
patients received CBTp+SC (25 protocol completers) and 30 patients received SC (18 
protocol completers in this part of the study). There were more drop-outs in the SC 
control group than the CBTp+SC group (Chi-square=4.022, p=0.045). Of those 
recruited to the CBTp+SC group, five patients left the study early (one patient 
discontinued therapy and four patients withdrew consent). Of those recruited to the 
SC control group, 12 patients dropped out (five patients withdrew consent; five 
patients did not undergo baseline MRI and were not followed-up, one patient moved 
to another area and could not be contacted, and one patient was incarcerated during 
the period of his scheduled follow-up). The five CBTp+SC non-completers did not 
differ from the CBTp+SC completers on pre-therapy clinical status and 
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neuropsychological function, whereas SC control non-completers had lower pre-
therapy scores on 2 out of 12 neuropsychological measures than SC control 
completers: Letter-Number test number of items correctly recalled: completers=13.22 
(2.58) and non-completers=9.30 (4.37), F=9.01, df=1,25, p=0.006; Hopkins verbal 
learning test number of items freely recalled: completers=22.39 (4.58) and non-
completers^ 7.78 (5.14), F=5.62, df=1,25, p=0.026. SC control completers and non-
completers did not differ on pre-therapy clinical status. 
All patients received a PANSS rating > 60, reported at least one positive 
'distressing' symptom of schizophrenia and wished to receive CBTp in addition to SC. 
Patients were on stable doses of antipsychotic medication for at least two years and 
on the current antipsychotic drug for at least three months prior to taking part (86% on 
atypical antipsychotics). Patients in both treatment groups were recruited from the 
South London and Maudsley (SLAM) NHS Foundation Trust, were identified by local 
psychiatric consultants as suitable for CBTp and wished to receive CBTp in addition 
to their usual care. Patients who were referred to and accepted for CBTp by the 
Psychological Interventions Clinic for Outpatients with Psychosis (PICuP), SLAM 
NHS Foundation Trust, went into the CBTp+SC group. Ninety-five patients were 
referred to PICuP, of whom 31% participated in the study, 23% did not wish to take 
part, 21% were not considered because they were either not fluent English speakers 
or had received CBTp in the past, 20% were not suitable for PICuP or withdrew 
before assessment of suitability for PICuP, and 3% were not suitable for MRI; the 
reason for non-inclusion of 2% was not known (most likely they missed their 
appointment). Those who did not wish to take part or were excluded had a similar 
age on average to those who took part. Patients who matched the CBTp+SC group 
patients demographically and clinically as much as possible were studied as part of 
the SC control group over the same interval as the CBTp+SC group patients. 
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Patients were recruited in a case-controlled manner. Although treatment allocation 
was not randomised, there was no discernable difference between CBTp+SC and SC 
control groups with regard to their suitability or desire to undergo the intervention. 
CBTp was delivered by trained therapists, and followed the procedure 
developed by Fowler et al. (1995). CBTp, as defined by the National Institute for 
Health and Clinical Excellence updated guidelines (NICE, 2009), consisted of 
enabling the patient to: (i) establish links between their thoughts, feelings or actions 
with respect to the current or past symptoms, and/or functioning; and (ii) re-evaluate 
their perceptions, beliefs or reasoning related to the target symptoms. In addition, 
CBTp involved enabling the patient to monitor his/her own thoughts, feelings or 
behaviours with respect to the symptom or recurrence of symptoms; and/or (i) 
promotion of alternative ways of coping with the target symptom, (ii) the reduction of 
distress, and/or (iii) the improvement of functioning. Therapy sessions were 
conducted on a weekly or fortnightly basis, as preferred by the patient. CBTp patients 
received an average of 19 (S.D. 7) therapy sessions. Treatment adherence was 
assessed by fortnightly supervision. In addition, a number of therapy sessions (n=13) 
were taped and rated independently by an experienced CBTp therapist for fidelity of 
treatment using the Cognitive Therapy Scale for Psychosis (Haddock et al., 2001). 
The mean rating was 40.7 (range 21-53) out of a maximum of 60, with 77% of the 
tapes scoring above the 50% mark (i.e. rating score>30). 
SC consisted of case management offered by the case management team for 
a particular geographical area. The case management included regular reviews with 
a dedicated care coordinator who monitored the patient's mental health needs, 
offered support and provided further specialist input, viz. regular reviews with a 
psychiatrist. The care coordinator also arranged for support from other specialists, 
such as a psychologist, vocational adviser, benefits adviser and occupational 
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therapist as needed. Six-monthly care plan assessment reviews were carried out 
with a focus on recovery. The patients in the SC control group were not receiving any 
control psychological intervention. 
The study procedures were approved by the ethics committee of the Institute 
of Psychiatry and the SLAM NHS Foundation Trust, London. All participants provided 
written informed consent to their participation and were compensated for their time in 
undergoing MRI scanning and clinical and neuropsychological assessments 
(participants were not paid for therapy) and travel. 
2.2. Clinical assessments 
Clinical diagnosis at baseline was confirmed by a consultant psychiatrist (DF) 
using the Structured Clinical Interview for DSM-IV (First et al., 2002). PANSS 
assessments (Kay et al., 1987) were performed on patients before and after CBTp by 
an experienced psychiatrist (DF). This psychiatrist played no role in patient 
recruitment or clinical management of the patients included in this investigation and 
was blind to whether or not a patient received CBTp in addition to their usual 
treatment. Clinical and neuropsychological assessments were carried out by 
doctoral-level researchers on patients at baseline and follow-up. Neuropsychological 
assessments in healthy participants were performed once (at baseline). 
2.2.1. Beck Depression Inventory-ll 
The Beck Depression Inventory-ll (Beck, 1996) is a 21-item questionnaire assessing 
the main emotional, cognitive and physiological symptoms of depression (Beck et al., 
1988b). The total score was used in the analysis. 
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2.2.2. Beck Anxiety Inventory 
The Beck Anxiety Inventory (Beck et al., 1988a) is a 21-item questionnaire assessing 
the main symptoms associated with anxiety disorder. The total score was used in the 
analysis. 
2.2.3. Rosenberg Self-esteem scale 
The Rosenberg Self-esteem Scale (Rosenberg, 1965) is a 10-item self-reported 
inventory. It measures overall feelings of self-worth or self-acceptance. Items are 
rated on a 4-point Likert Scale from 'Strongly Agree' to 'Strongly Disagree'. The total 
score was used in the analysis. 
2.2.4. Beck Cognitive Insight scale 
The Beck Cognitive Insight scale (Beck et al., 2004) is a 15-item self-reported 
inventory. The items separate into two factors, namely self-certainty and self-
reflectiveness. The composite score on this scale is derived from the difference 
between self-certainty and self-reflectiveness. 
2.2.5. Schedule for the Assessment of Insight - expanded 
The Schedule for the Assessment of Insight - expanded (SAI-E) (Kemp and David, 
1997) is a 9-item researcher administered inventory relating to the patient's 
awareness of illness and specific symptoms, illness attribution, awareness of illness 
consequences, treatment compliance, symptom re-labelling, and openness to 
contradiction of his/her beliefs. The total score was used in the analysis. 
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2.2.6. Birchwood Insight scale 
The BIS (Birchwood et al., 1994) is an 8-item self-reported inventory. Items include 
"Some of my symptoms are made by my mind" and "The doctor is right in prescribing 
medication for me". Item 4 "My stay in hospital is necessary" was disregarded, as all 
patients were outpatient. The total score was used in the analysis. 
2.2.7. Coping Orientation to Problems Experience 
The Coping Orientation to Problems Experience (COPE) inventory (Carver et al., 
1989) is a 60-item self-reported coping inventory which assesses the ways in which 
individuals respond to stress based on the theoretical principles underlying Lazarus' 
model of stress (Lazarus, 1966; Lazarus and Folkman, 1984). The format used in the 
present study asked respondents to indicate how they had been coping with the 
stress in their life since they were told that they had a mental health problem. The 
scale consists of 15 subscales, namely Positive reinterpretation and growth, Mental 
disengagement, Focus on and venting of emotions, Use of instrumental social 
support, Active coping, Denial, Religious coping, Behavioural disengagement, 
Restraint, Use of emotional social support, Substance use, Suppression of competing 
activities, Acceptance, Planning and Humour. The total and subscale scores were 
used in the analysis. 
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2.3. Neuropsychological assessments 
2.3.1. General intelligence 
2.3.1.1.Wechsler Abbreviated Scale of Intelligence 
The Wechsler Abbreviated Scale of Intelligence (WASI, Wechsler, 1999) is 
designed to be a short test of general intellectual ability. The two-subtest version of 
the WASI consists of the Vocabulary subtest and the Matrix Reasoning subtest. The 
subtests were combined to estimate full-scale equivalent current IQ. 
2.3.1.2. National Adult Reading test 
The National Adult Reading test (Nelson and Wilson, 1991) is a measure of 
premorbid IQ. Selection of the word list in this test is based on the existence of 
atypical words that do not follow the common rules of grapheme-phoneme 
representation and pronunciation. Predicted premorbid IQ was the variable used in 
the analysis. 
2.3.2. Executive function 
2.3.2.1. Behavioural Assessment of Dysexecutive Syndrome 
The Behavioural Assessment of Dysexecutive Syndrome (BADS, Wilson et 
al., 1996) is a test of executive functioning comprising six subtests: Rule Shift Cards, 
Action Program Test, Temporal Judgement Test, Key Search Test, Zoo Map Test, 
and the Modified Six Elements. Each subtest has a range of scores of 0 to 4. Total 
profile score was the variable used in the analysis. 
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2.3.2.2. Brixton Spatial Anticipation test 
The Brixton Spatial Anticipation test (BSAT, Burgess and Shallice, 1997) is a 
test of concept formation in which the participant is presented with a sequence of 56 
near-identical stimuli, each of which has 10 circles, one of which is coloured blue. 
The participant is instructed to point to the expected position of a coloured circle on 
the next page. The location of this coloured circle is determined by one of nine rules 
based on the previous position of the coloured circle. The number of perseverative 
errors was used in the analysis. 
2.3.2.3. Wisconsin Card Sorting test 
The computerised version of the Wisconsin Card Sorting test (WCST, Heaton 
et al., 1993) was used. Participants are asked to match the choice-card to the upper 
panel of cards using a hidden rule. Successful completion of the WCST requires 
participants to (a) attain concept or the current rule, (b) maintain the concept for 10 
consecutive trials and (c) switch the concept when the sorting rule is changed. 
Number of perseverative errors was used in the analysis. 
2.3.3. Working memory 
2.3.3.1. Letter Number test 
In this task (Gold et al., 1997), participants are asked to recall a string of 
letters and numbers, placing the numbers first in ascending order, followed by the 
letters in alphabetical order. Total number of correct items was used in the analysis. 
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2.3.4. Immediate verbal learning and memory 
2.3.4.1. Wechsler Memory Scale III - Logical Memory 
In this subtest of the Wechsler Memory Scale - III (Wechsler, 1998), the 
participant listens to two different stories read by the examiner and is asked to retell it 
from memory immediately after hearing each story (immediate recall) and half an 
hour later (delayed recall). Immediate and delayed unit recall scaled scores were 
used in the analysis. 
2.3.4.2. Hopkins Verbal Learning test - Revised 
In the free recall part of the Hopkins Verbal Learning test (Shapiro et al., 
1999), the examiner reads out a list of 12 words which the participant is asked to 
recall. The list is read out three times and the number of words correctly recalled on 
each occasion is noted. Total number of items freely recalled was used in the 
analysis. 
2.3.5. Attention 
2.3.5.1. Continuous Performance Test - Identical Pairs (CPT-IP) 
This test (Cornblatt et al., 1988) requires the participant to respond when two 
identical stimuli appear consecutively on the computer screen. Stimuli (four-digit 
numbers) are flashed on the screen at a constant rate of one stimulus per second, 
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with a stimulus "on" time of 50 ms. Target trials are the second stimulus of a pair of 
identical stimuli. Discriminability index was used in the analysis. 
2.3.6. Verbal skills 
2.3.6.1. Verbal fluency test 
The Verbal fluency test (Milner, 1975) requires the participant to generate as 
many words as possible starting with a specified letter or a specified category within 
60 seconds. Word generation is based on one of three letters: F, A and S, and on 
one of three categories: animal, fruit and vegetable. Number of correct words 
generated in each subtest was used in the analysis. 
2.3.7. Cognitive inhibition 
2.3.7.1. Hay ling Sentence Completion test 
The Hayling Sentence Completion Test (HSCT, Burgess and Shallice, 1997) 
requires the participant to provide single-word completions to sentences, each of 
which has the last word missing. There are two parts: in part A, participants must 
produce sensible completions as quickly as possible; in part B, the participant must 
produce completions that are unrelated to the preceding sentence. The time taken to 
complete the two parts as well as the errors made in part B are converted into a 
scaled score. Hayling B scaled score was used in the analysis. 
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2.3.8. Emotional decision-making 
2.3.8.1. Iowa Gambling Task 
In the Iowa Gambling Task (IGT) (Bechara et al., 1994), participants choose 
cards from advantageous and disadvantageous decks, such that choosing from the 
disadvantageous decks is associated with greater immediate monetary reward 
compared to the advantageous decks, but an overall greater monetary loss compared 
to the advantageous decks. The trials are presented in five blocks. Overall learning 
(score on Block 5 minus Block 1) was used in the analysis. 
2.4. Statistical analysis 
2.4.1. Comparison of patient group characteristics at baseline 
Due to the large number of neuropsychological measures (n=12), individual 
test scores were combined within each domain to provide composite domain scores 
at baseline and follow-up (see Section 2.3 Neuropsychological Assessments for tests 
included in each domain) based on the approach followed by Kern et al. (2008). The 
patient groups were compared on gender using Chi-squared test, and baseline 
clinical and neuropsychological domain variables using analysis of variance or Mann-
Whitney U-tests for variables with significant heterogeneity of variance (number of 
years in education, duration of illness, Birchwood Insight scale total score, working 
memory, verbal skills and emotional decision-making domain scores). 
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2.4.2. Change in clinical status and neuropsychological ability from 
baseline to follow-up 
Absolute change from baseline to follow-up was computed for each clinical 
and neuropsychological domain variable (calculated so that a negative change score 
indicated improvement in clinical status or neuropsychological function at follow-up). 
For all clinical measures (except BCI composite index subscale), a higher score on 
the scale indicates greater severity. Therefore, change on these clinical measures 
was calculated as follow-up score minus baseline score (except for BCI composite 
index subscale, where change was calculated as baseline score minus follow-up 
score). For all neuropsychological domain scores, a higher score indicates better 
performance. Therefore, change on neuropsychological domain scores was 
calculated as baseline score minus follow-up score. Analyses of co-variance were 
carried out in order to compare the change in clinical and neuropsychological domain 
scores in the two patient groups with baseline clinical or neuropsychological domain 
score as the covariate. For variables with significant heterogeneity of variance in the 
change scores between patient groups (verbal skills), Mann-Whitney U tests were 
performed. 
2.4.3. Pre-therapy clinical predictors of symptom change 
Analysis of variance with gender as the independent variable and residual 
change in PANSS total, positive, negative and general psychopathology symptom 
ratings as the dependent variable was performed in the CBTp+SC group. For the 
purpose of this analysis, symptom change was estimated as the residual change in 
PANSS symptoms (change in symptom scores covarying for baseline symptom 
scores) (Siegle et al., 2006). Although other variables were also found to have 
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changed significantly at follow-up (Results, section 3.2 'Change in clinical status and 
neuropsychological ability following CBTp'), given the modest sample sizes we limited 
our analyses to predictors of psychotic symptom change. Pearson correlations, or 
Spearman correlations for variables with significant kurtosis or skewness 
(antipsychotic medication level and Birchwood Insight total score), were performed 
between pre-therapy clinical variables and symptom change scores in the CBTp+SC 
and SC control groups separately. In order to determine whether the pre-therapy 
clinical variables found to significantly predict CBTp responsiveness had a differential 
effect on outcome in the CBTp+SC relative to SC control group, correlations were 
repeated in the SC control group for those correlations found to be significant in the 
CBTp+SC group. The correlation coefficients from the two groups were compared 
using Fisher's ztransformation (Howell, 2002). 
Finally, Pearson correlations were performed between number of CBTp 
therapy sessions and symptom change scores in order to examine whether this factor 
was related to treatment outcome. 
As the aforementioned correlational analyses showed that pre-therapy COPE 
total, BCI self-reflectiveness and BCI composite index scores correlated with 
symptom change following CBTp (Results, Section 3.3), multiple regression analyses 
were performed to determine which pre-therapy clinical variable contributed more 
strongly to the variance in the criterion variable (symptom change) in the CBTp+SC 
group. Predictor variables (pre-therapy COPE total, BCI self-reflectiveness and BCI 
composite index scores) were entered in a stepwise manner (to estimate the effect of 
individual predictors on the variability of the criterion variable) and using a standard 
regression (all predictors were entered simultaneously and results were given for only 
one step to explain the combined effect of predictors on the variability of the criterion 
variable). 
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2.4.4. Pre-therapy neuropsychological correlates of symptom 
change 
Pearson correlations were performed between pre-therapy 
neuropsychological domain scores and symptom change scores following CBTp in 
CBTp+SC patients. 
All analyses were performed in SPSS (version 15). Alpha level for testing 
significance of effects was maintained at p<0.05, except for the correlations between 
COPE subscales and symptom change where a higher threshold of p<0.01 was 
adopted. 
3. Results 
3.1. Characteristics of patient groups at baseline 
The CBTp+SC group had lower BCI self-certainty, greater BCI composite 
index, and greater SAI total scores than the SC control group at baseline (see Table 
1). The CBTp+SC group had higher general IQ and verbal skills and tended to have 
better attention than the SC control group at baseline (see Table 1 and Figure 1). 
**** Table 1 about here **** 
**** Figure 1 about here **** 
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3.2. Change In clinical status and neuropsychological ability 
following CBTp 
The CBTp+SC group showed greater improvement from baseline to follow-up 
than the SC control group on total, positive, negative and general psychopathology 
symptom ratings, as well as self-reported depression and self-esteem, with a trend 
towards improvement in BCI self-certainty (lower self-certainty) (see Table 2). 
There were no significant differences in outcome between the groups on 
anxiety, clinical insight and BCI composite index, coping skills, or any of the 
neuropsychological domains (see Table 2). 
**** Table 2 about here **** 
3.3. Pre-therapy clinical and neuropsychological predictors of 
CBTp responsiveness 
There was no effect of gender on symptom change in the CBTp+SC group 
(total symptoms change, F=0.241, df=1,11, p=0.632; positive symptoms change, 
F<0.001,df=1,11, p=0.990; negative symptoms change, F=0.151, df=1,11, p=0.700; 
general psychopathology change, F=1.593, df=1,11, p=0.233). 
Greater BCI self-reflectiveness scores at baseline correlated with 
improvement in total symptom ratings in the CBTp+SC group (r=0.409, p=0.042), but 
not the SC control group (r=-0.180, p=0.475) (see Table 3). These correlation 
coefficients differed between groups (z=1.845, p=0.033). Greater BCI self-
reflectiveness at baseline also correlated with improvement in negative symptoms in 
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the CBTp+SC group (r=0.419, p=0.037), but not the SC control group (r=-0.054, 
p=0.831). These correlation coefficients differed between groups at a trend level 
(z=1.487, p=0.068). 
Greater BCI composite scores at baseline correlated with improvement in total 
symptoms in the CBTp+SC group (r=0.419, p=0.037), but not in the SC control group 
(r=-0.227, p=0.364). These correlation coefficients differed between groups (z=2.022, 
p=0.020). Greater BCI composite scores at baseline also correlated with 
improvement in general psychopathology symptoms in the CBTp+SC group (r=0.426, 
p=0.034), but not in the SC control group (r=-0.155, p=0.540). Again, these 
correlation coefficients differed between groups (z=1.822, p=0.030). 
Greater coping ability at baseline correlated with improvement in total 
symptoms in the CBTp+SC group (r=0.496, p=0.022), but not in the SC control group 
(r=0.043, p=0.874).1 These correlation coefficients differed between groups at a trend 
level (z=1.382, p=0.085). Greater coping ability at baseline also correlated with 
improvement in negative symptoms in the CBTp+SC group (r=0.450, p=0.041), but 
not in the SC control group (r=-0.056, p=0.838). These correlation coefficients 
differed between groups at a trend level (z=1.4842, p=0.069). Lastly, greater coping 
ability at baseline correlated with improvement in general psychopathology symptoms 
1
 The following COPE subscales correlated positively with improvement in total symptoms in the 
CBTp+SC group: active coping (Spearman's rho=0.657, p=0.001), suppression of competing activities 
(rho=0.485, p=0.026) and acceptance (rho=0.440, p=0.046). The following COPE subscales correlated 
positively with improvement in negative symptoms: planning (rho=0.596, p=0.004), active coping 
(rho=0.473, p=0.030) and use of emotional social support (rho=0.465, p=0.034). The following COPE 
subscales correlated positively with improvement in general psychopathology symptoms: planning 
(rho=0.671, p=0.001), active coping (rho=0.498, p=0.022) and suppression of competing activities 
(rho=0.489, p=0.024). Behavioural disengagement correlated negatively with improvement in general 
psychopathology symptoms (rho=-0.430, p=0.052). 
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in the CBTp+SC group (r=0.424, p=0.055), but not in the SC control group (r=0.168, 
p=0.533). These correlation coefficients did not differ between groups (z=0.788, 
p=0.215). 
In the CBTp+SC group, there were no significant correlations between 
symptom change from baseline to follow-up and illness duration, age of onset, level of 
antipsychotic medication, self-reported depression and anxiety, clinical insight, self-
esteem, BCI self-certainty, number of therapy sessions and any of the 
neuropsychological domains at baseline (see Table 3). 
A stepwise multiple regression (stepwise model: multiple R=0.496, F=6.215, 
p=0.022) of pre-therapy COPE total, BCI self-reflectiveness and BCI composite index 
scores on total symptom change scores in the CBTp+SC group revealed that COPE 
total was a significant predictor and explained 20.7% of the variance in total symptom 
change. Together (standard regression model: multiple R=0.577, F=2.835, p=0.069), 
the three pre-therapy clinical predictors together explained 21.6% of the variance in 
total symptom change. 
A stepwise multiple regression (stepwise model: multiple R=0.450, F=4.828, 
p=0.041) of pre-therapy COPE total and BCI self-reflectiveness scores on negative 
symptom change scores in the CBTp+SC group revealed that COPE total was a 
significant predictor and explained 16.1% of the variance in negative symptom 
change. Together (standard regression model: multiple R=0.521, F=3.359, p=0.058), 
the two pre-therapy clinical predictors explained 19.1% of the variance in negative 
symptom change. 
The standard, but not the stepwise, multiple regression of pre-therapy COPE 
total and BCI composite scores on general psychopathology symptom change in the 
CBTp+SC group was significant (multiple R=0.532, F=3.550, p=0.050). Pre-therapy 
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COPE total and BCI composite index scores together explained 20.3% of the 
variance in general psychopathology severity change. 
**** Table 3 about here **** 
4. Discussion 
The present study investigated (a) the pre-therapy clinical and 
neuropsychological predictors of CBTp and (b) the change in clinical status and 
neuropsychological function following CBTp. The findings from these investigations 
will be discussed in turn. 
4.1. Clinical and neuropsychological predictors of CBTp 
responsiveness 
Three pre-therapy clinical variables emerged as significant predictors of total 
symptom improvement following CBTp, namely coping, and two out of the three 
Cognitive Insight Scale (Beck et al., 2004) scores, namely self-reflectiveness and the 
composite index score (being able to self-reflect while refraining from overconfidence 
in one's judgements). Pre-therapy cognitive insight and coping predicted symptom 
improvement more strongly in the CBTp+SC than the SC control group, suggesting 
that they are specific predictors of CBTp responsiveness rather than of good outcome 
in general, although the size of the difference in the coping-symptom change relation 
between the CBTp and SC control groups was weaker than the cognitive insight-
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symptom change relation. Therefore, coping and cognitive insight (participants' 
intrinsic ability to reappraise misinterpretations), rather than clinical insight, duration of 
illness, gender or neuropsychological function, appeared to be the important factors in 
predicting symptom improvement following CBTp. However, these relationships were 
significant for negative and general, but not positive, symptom improvement. 
Pre-therapy coping was found to be the strongest of the three significant 
predictors of change. Several pre-therapy coping strategies were associated with 
CBTp responsiveness (e.g. active coping, planning and use of emotional social 
support). The pattern of our findings is consistent with the view that patients with 
schizophrenia who have a wide repertoire of coping strategies and are flexible about 
their coping responses are more likely to experience psychological well-being (Phillips 
et al., 2009). Active coping is the process of taking active steps to try to remove or 
circumvent the stressor or ameliorate its effects (Carver et al., 1989). Active coping 
includes initiating direct action, increasing one's efforts and trying to execute a coping 
attempt in stepwise fashion (Carver et al., 1989). Planning is thinking about how to 
cope with a stressor. Planning involves coming up with action strategies, thinking 
about what steps to take and how best to handle the problem. Being able to plan a 
coping response and then actively carry out the response may moderate CBTp's aim 
to alleviate general distress (i.e. reduce general symptoms) and increase functioning 
(i.e. reduce negative symptoms), although it does not appear to be related to outcome 
for positive symptoms. 
4.1.1. Insight and CBTp responsiveness 
The ability to reflect on one's anomalous experiences (self-reflectiveness) 
before therapy predicted improvement in negative symptoms in the CBTp+SC, but not 
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the SC control, group. Being able to self-reflect while refraining from overconfidence 
in one's judgements (composite index) before therapy predicted improvement in 
general psychopathology in the CBTp+SC group, but not the SC control group. 
These findings support and extend those of Perivoliotis et al. (2010) and Garety et al. 
(1997) by demonstrating that cognitive insight or flexibility may be related to 
improvements in negative and general symptoms. Having some ability to re-evaluate 
perceptions, beliefs and reasoning beforehand may therefore benefit CBTp 
responsiveness in a number of different areas. Greater self-reflectiveness is 
associated with lower severity of positive and negative symptoms (Bora et al., 2007). 
In the present study, overconfidence about one's interpretations per se did not predict 
symptom improvement. This lack of a relationship may be because the level of 
delusional beliefs in our group of patients before therapy may have been at a 
moderate level, and overconfidence about judgements, which may be equivalent to 
the jumping-to-conclusions (JTC) reasoning style, is thought to underlie delusional 
beliefs (Garety and Freeman, 1999). In one study (Warman and Martin, 2006), 
patients with schizophrenia or schizoaffective disorder who had active delusions 
tended to endorse their beliefs and judgements more readily than healthy participants 
who were delusion-prone and healthy participants with no delusional proneness, i.e. 
the patients with active delusions expressed more confidence in their judgements 
about the emotional salience of personally relevant statements. Brabban et al. (2009) 
found that a lower level of conviction about delusions predicted a greater likelihood of 
improvement in general psychopathology only in patients with delusions. The present 
study and an earlier study (Perivoliotis et al., 2010) suggest that the composite index 
is different conceptually from the individual subscales and shed light on the nature of 
the Cognitive Insight scale. The results suggest that refraining from overconfidence 
in one's judgements on its own does not predict symptom improvement, but does in 
the context of being able to self-reflect. The composite index takes into account the 
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fact that the two subscales are not mutually exclusive (Beck et al., 2004; Warman et 
al., 2007). 
In the multiple regression analyses of pre-therapy predictors of CBTp 
responsiveness, pre-therapy cognitive insight did not add significantly to the variance 
of the model explained by pre-therapy coping. This may have been because of the 
similar processes involved in coping and cognitive insight, as suggested by the 
overlapping variances of these variables. Clinical insight and coping have already 
been shown to work congruently in alleviating symptoms in patients with psychosis 
(Cooke et al., 2007; Lysaker et al., 2005; Phillips et al., 2009). Those who are able to 
successfully 'integrate' their illness with their view of themselves are more likely to 
develop successful coping strategies than those who 'seal over' and perceive their 
illness as negative and interrupting the progress of their lives (Phillips et al., 2009). 
Cooke et al. (2007) observed a range of associations between clinical insight and 
coping. Specifically, better use of instrumental support and planning were associated 
with better illness insight in schizophrenia patients, and lesser mental disengagement 
and better ability to suppress competing activities with better awareness of problem. 
Unlike previous studies (Emmerson et al., 2009; Naeem et al., 2008), we did not find 
pre-therapy clinical insight to predict symptom improvement following CBTp. 
However, the Insight trial (Naeem et al., 2008) was specifically targeting insight as a 
treatment goal, and Emmerson et al. (2009) were targeting independent living skills, 
unlike the therapy delivered in this study, which was more similar to that implemented 
by Garety et al. (1997), who also did not find that clinical insight was a predictor of 
change. 
In the present study, pre-therapy neuropsychological functioning did not 
predict CBTp responsiveness, which is mainly consistent with previous studies 
(Garety et al., 1997; Penades et al., 2010). Although Penades et al. (2010) reported 
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verbal memory to predict improvement in positive symptoms, their sample comprised 
patients with a slightly longer duration of illness [mean (S.D.)=14.9 (1.2)] than our 
sample [mean (S.D.)=11.73 (7.89)]. Penades et al. (2010) also used a categorical 
approach to define whether patients were 'improvers' or 'non-improvers', while the 
present study's comparison consisted of outcome in people receiving CBTp+SC 
versus SC. We earlier reported (Premkumar et al., 2009) that CBTp+SC responders 
had larger posterior hippocampal volume than CBTp+SC non-responders, which 
given that greater hippocampal volume is related to better learning and memory in 
schizophrenia patients (Antonova et al., 2004; Nestor et al., 2007; Rametti et al., 
2007), is consistent with the Penades et al. study findings. Specific measures of 
cognitive control and self-versus-other discrimination may also be more relevant to 
CBTp response (Kumari et al., 2010; Kumari et al., 2009). Future studies may also 
examine whether pre-therapy neuropsychological measures related to cognitive 
insight, such as the meta-cognition task (Lysaker et al., 2009), are related to symptom 
improvement following CBTp. We also did not observe the effect of gender or 
duration of illness on symptom improvement that has been previously reported 
(Brabban et al., 2009; Tarrier et al., 1998). It is possible that gender effects may be 
specific to certain CBTp formats, as women responded better to brief CBTp (6 
sessions over 3 months) than men (Brabban et al., 2009), and duration of illness may 
predict CBTp when therapy is combined with coping skills enhancement (Tarrier et 
al., 1998). 
4.2. Changes in clinical status following CBTp 
The levels of depression and self-esteem and, at a near significant level, self-
certainty improved to a greater extent in the CBTp+SC than SC control group, in 
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addition to PANSS symptoms. Our findings support a number of studies 
demonstrating significant improvements in depression (Garety et al., 2008; Peters et 
al., 2010) and increased self-esteem (Gumley et al., 2006). Although self-certainty 
did not predict CBTp responsiveness, possibly because such an association may be 
observed in patients with a greater level of delusions (Brabban et al., 2009), it 
somewhat improved following CBTp in the present study. CBTp may help patients to 
refrain from overconfidence in their beliefs and inferences of anomalous experiences 
regardless of the presence of delusional beliefs. 
4.3. Limitations and future research 
The moderate sample sizes of the CBTp+SC and SC control groups may not 
have allowed sufficient power to demonstrate significant group differences in the pre-
therapy coping-symptom improvement relationships. This study, like most studies on 
coping strategies in psychosis (Phillips et al., 2009), used a relatively small number of 
outpatients who mostly had a paranoid schizophrenia diagnosis. This sample 
represents a relatively stable population of patients who have greater access to social 
and community-based systems than would their inpatient counterparts, and may use 
different coping strategies to inpatients (Phillips et al., 2009). Further research is 
needed to test this possibility. In addition to patients with schizophrenia, CBTp is 
found to be effective in patients in the early initial prodromal state of the pre-psychotic 
phase (Bechdolf et al., 2005; Morrison et al., 2004). Future research should also 
analyse the role of cognitive insight and coping in the efficacy of CBTp in pre-
psychotic phase. 
The CBTp+SC group had greater pre-therapy cognitive insight, general IQ and 
verbal skills than the SC control group at baseline, which may have contributed to 
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their better outcome, and confounded the pre-therapy cognitive insight-symptom 
change correlations. It is unlikely that the CBTp group would have improved to the 
same extent without CBTp over the course of this study, but it is possible that the SC 
control group would show less improvement with CBTp when offered as a result of 
lower pre-therapy level of insight. A greater number of drop-outs in the SC control, 
than CBTp+SC, group may also have led to a bias in some of the findings. 
4.4. Conclusions 
Coping styles and cognitive insight before therapy play a role in determining 
CBTp efficacy in patients with schizophrenia, specifically for negative and general 
symptoms. Being able to reflect on one's psychotic experiences and reappraise 
misinterpretations while refraining from being overconfident about one's 
interpretations, as well as having a range of coping strategies, especially planning 
and active coping, are related to better CBTp responsiveness. 
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Figure legends 
Figure 1. Pre-therapy standardized T-scores of neuropsychological domains in 
CBTp+SC (n=25), SC control (n=18) and healthy participant groups (n ranging from 
19 to 25 in different domains) 
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Table 1. Clinical and neuropsychological characteristics at baseline in CBTp+SC and SC control groups 
Characteristic 
Gender (number of males/females) 
Age 
Years in education 
Duration of illness 
Age of onset 
Medication dosage- CPZ equivalent 
PANSS symptoms at baseline 
Positive 
Negative 
General psychopathology 
Total 
BDI 
BAI 
Rosenberg Self-esteem 
BCI self-reflectiveness 
BCI self-certainty 
BCI composite 
SAI total 
Birchwood insight total 
COPE total 
Neuropsychological domain 
General intelligence 
Executive function 
Working memory 
Immediate verbal learning and memory 
Attention 
Verbal skills 
Cognitive inhibition 
Emotional decision-making 
CBTp+SC (n= 
N 
25 
25 
25 
25 
25 
25 
25 
25 
25 
25 
24 
25 
25 
25 
25 
25 
24 
25 
21 
25 
25 
25 
25 
25 
25 
25 
25 
Mean 
17/8 
36.08 
14.04 
11.73 
24.36 
526.15 
17.96 
17.84 
32.72 
68.52 
15.75 
14.16 
23.88 
16.28 
5.84 
10.44 
13.18 
9.68 
73.86 
41.13 
38.63 
42.21 
36.12 
42.54 
44.01 
46.03 
45.82 
25) ! 
SD I 
8.02 
2.91 
7.89 
8.01 
385.78 
4.74 
4.36 
7.21 
13.53 
8.29 
10.81 
6.24 
5.81 
3.58 
7.17 
5.88 
2.14 
28.15 
12.31 
19.60 
12.55 
9.18 
8.48 
8.64 
11.99 
13.08 
3C control (18) 
NJ 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
7 
8 
8 
8 
7 
8 
6 
8 
8 
8 
8 
8 
8 
8 
8 
Mean 
15/3 
39.72 
13.28 
14.50 
25.22 
459.65 
18.33 
19.05 
35.50 
72.89 
16.44 
20.06 
23.18 
13.44 
8.44 
5.00 
10.61 
5.17 
82.87 
32.75 
31.45 
39.49 
35.98 
37.91 
37.40 
42.04 
44.11 
SD 
10.49 
1.93 
12.10 
8.24 
336.47 
3.45 
3.89 
4.19 
9.01 
10.18 
12.20 
5.68 
5.40 
3.60 
7.04 
5.24 
2.12 
29.75 
14.88 
10.86 
8.19 
8.78 
6.75 
5.75 
13.95 
8.73 
For 
F 
Z 
Z 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
Z 
F 
F 
F 
Z 
F 
F 
Z 
F 
Z 
Statistic 
1.688 
0.696 
0.444 
0.188 
0.345 
0.081 
0.888 
2.146 
1.417 
0.059 
2.795 
0.138 
2.643 
5.514 
6.122 
4.767 
1.796 
0.888 
4.074 
1.968 
0.496 
0.003 
3.681 
2.511 
1.014 
<0.001 
df 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,40 
1,41 
1,40 
1,41 
1,41 
1,41 
1,39 
1,41 
1,35 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
1,41 
P 
0.204 
0.487 
0.657 
0.733 
0.560 
0.778 
0.352 
0.151 
0.241 
0.809 
0.102 
0.712 
0.112 
0.024 
0.018 
0.035 
0.072 
0.353 
0.050 
0.168 
0.620 
0.959 
0.062 
0.012 
0.320 
1.000 
Values in bold: significant difference between patient groups at p < 0.05; fMann-Whitney U test (Z statistic) performed for variables 
with significant variance heterogeneity between groups. 
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Table 2. Change in clinical and neuropsychological status from baseline to follow-up in CBTp+SC and SC control groups controlling 
for clinical status at baseline 
Clinical variable 
PANSS symptoms 
Positive 
Negative 
General psychopathology 
Total symptoms 
BDI 
BAI 
Rosenberg self-esteem 
BCI self-reflectiveness 
BCI self-certainty 
BCI composite 
SAI total* 
Birchwood insight total 
COPE total 
Neuropsychological domain 
Executive function 
Working memory 
Immediate verbal learning and 
memory 
Attention 
Verbal skills 
Cognitive inhibition 
Emotional decision-making 
N 
25 
25 
25 
25 
23 
23 
25 
25 
25 
25 
14 
25 
21 
18 
24 
25 
24 
24 
24 
23 
CBTp 
Mean 
-3.04 
-2.36 
-4.68 
-10.08 
-5.57 
-4.26 
-1.04 
-1.48 
-1.52 
0.04 
0.89 
-0.27 
-2.00 
-2.40 
-2.82 
-5.55 
-1.30 
-1.28 
-2.22 
-0.35 
+SC 
SD 
4.05 
3.81 
7.42 
12.93 
10.17 
10.71 
6.15 
4.69 
3.87 
3.55 
5.46 
1.80 
27.28 
16.57 
10.10 
7.75 
7.55 
5.13 
11.94 
16.42 
N 
18 
18 
18 
18 
17 
17 
17 
16 
16 
17 
9 
16 
13 
13 
17 
17 
17 
17 
17 
17 
SC control 
Mean 
-0.56 
0.72 
-0.83 
-0.67 
0.76 
-3.18 
2.25 
<-0.001 
-0.37 
0.37 
2.63 
-0.27 
-0.77 
-7.83 
-1.81 
-3.23 
-2.68 
-1.19 
-1.39 
1.82 
SD 
3.79 
4.67 
6.70 
12.19 
7.50 
12.61 
3.84 
4.26 
3.67 
6.16 
3.61 
1.87 
20.55 
12.98 
7.46 
7.50 
7.94 
3.25 
20.66 
11.83 
For 
ZT 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
Z 
F 
F 
Statistic 
6.246 
9.551 
6.772 
8.664 
4.775 
2.864 
4.069 
0.045 
3.791 
0.398 
0.710 
0.244 
0.531 
0.494 
0.681 
1.160 
0.033 
0.132 
0.535 
2.288 
p 
0.017 
0.004 
0.013 
0.005 
0.035 
0.099 
0.051 
0.833 
0.059 
0.532 
0.409 
0.624 
0.472 
0.488 
0.414 
0.288 
0.856 
0.895 
0.469 
0.139 
Values in bold: significant difference between patient groups at p < 0.05; negative mean score indicates improvement in clinical or 
neuropsychological status; tMann-Whitney U test (Z statistic) performed for variables with significant variance heterogeneity between 
groups; tSAI total score at follow-up was available only for patients who had a score >4 on a PANSS positive item. 
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Table 3. Correlation between baseline clinical status and symptom change in CBTp+SC 
patients 
Baseline clinical variable 
Duration of illness 
Age of onset 
fMedication dosage (CPZ 
equivalent) 
BDI 
BAI 
Rosenberg Self-Esteem 
BCI self-reflectiveness 
BCI self-certainty 
BCI composite 
SAI total 
fBirchwood insight total 
COPE total 
Number of therapy sessions 
Neuropsychological domain 
General intelligence 
Executive function 
Working memory 
Immediate verbal learning and 
memory 
Attention 
Verbal skills 
Cognitive inhibition 
Emotional decision-making 
N 
25 
25 
25 
24 
25 
25 
25 
25 
25 
24 
25 
21 
22 
25 
25 
25 
25 
25 
25 
25 
25 
PANSS 
Total 
-0.066 
(0.753) 
0.380 
(0.061) 
0.019 
(0.929) 
0.179 
(0.402) 
0.077 
(0.716) 
0.176 
(0.399) 
0.409 
(0.042) 
-0.175 
(0.401) 
0.419 
(0.037) 
0.094 
(0.663) 
-0.176 
(0.401) 
0.496 
(0.022) 
-0.116 
(0.608) 
-0.385 
(0.057) 
-0.006 
(0.976) 
-0.176 
(0.401) 
-0.120 
(0.569) 
-0.290 
(0.159) 
-0.055 
(0.793) 
-0.213 
(0.306) 
0.168 
(0.422) 
PANSS 
Positive 
-0.092 
(0.661) 
0.305 
(0.139) 
-0.152 
(0.469) 
0.087 
(0.685) 
0.062 
(0.768) 
0.068 
(0.747) 
0.210 
(0.313) 
-0.240 
(0.247) 
0.290 
(0.159) 
0.316 
(0.132) 
0.263 
(0.204) 
0.378 
(0.091) 
-0.137 
(0.543) 
-0.318 
(0.121) 
0.017 
(0.934) 
-0.248 
(0.233) 
-0.125 
(0.550) 
-0.339 
(0.097) 
0.007 
(0.973) 
-0.082 
(0.698) 
0.179 
(0.393) 
PANSS 
Negative 
-0.096 
(0.647) 
0.247 
(0.235) 
0.329 
(0.109) 
0.338 
(0.107) 
0.026 
(0.902) 
0.371 
(0.068) 
0.419 
(0.037) 
-0.009 
(0.966) 
0.344 
(0.092) 
-0.080 
(0.711) 
-0.134 
(0.524) 
0.450 
(0.041) 
0.083 
(0.715) 
-0.326 
(0.112) 
-0.057 
(0.788) 
-0.104 
(0.621) 
0.048 
(0.820) 
-0.185 
(0.375) 
-0.081 
(0.700) 
-0.189 
(0.366) 
0.185 
(0.377) 
PANSS General 
psychopathology 
-0.047 
(0.823) 
0.379 
(0.062) 
0.075 
(0.722) 
0.122 
(0.569) 
-0.007 
(0.975) 
0.113 
(0.592) 
0.376 
(0.064) 
-0.244 
(0.240) 
0.426 
(0.034) 
0.063 
(0.771) 
-0.150 
(0.475) 
0.424 
(0.055) 
-0.200 
(0.373) 
-0.333 
(0.104) 
0.015 
(0.945) 
-0.171 
(0.413) 
-0.170 
(0.415) 
-0.231 
(0.266) 
-0.012 
(0.954) 
-0.289 
(0.161) 
0.150 
(0.473) 
Values in bold: significant correlation at p < 0.05; tSpearman's rho correlation performed for 
this variable. 
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